Stockscreener 앱 받기
6.26
1.88%
-0.12
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Is Entrada Therapeutics Inc. a good long term investmentDynamic profit opportunities - Jammu Links News
What analysts say about Entrada Therapeutics Inc. stockRemarkably fast returns - Jammu Links News
What makes Entrada Therapeutics Inc. stock price move sharplyFree Stock Investment Growth Plan - newser.com
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
How Entrada Therapeutics Inc. stock performs during market volatilityTrend Based Entry Alerts - Newser
Allspring Global Investments Holdings LLC Has $149,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World
5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k - Investing.com Nigeria
5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k By Investing.com - Investing.com South Africa
Entrada therapeutics (TRDA) director Parmar sells $202k in stock By Investing.com - Investing.com South Africa
Entrada therapeutics (TRDA) director Parmar sells $202k in stock - Investing.com Australia
(TRDA) Investment Analysis and Advice - news.stocktradersdaily.com
Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% – Should You Sell? - Defense World
Entrada Therapeutics (TRDA) 10% owners sell $866k in stock - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Upgraded to “Hold” at Wall Street Zen - Defense World
(TRDA) Long Term Investment Analysis - news.stocktradersdaily.com
Harbor Capital Advisors Inc. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Bank of America Corp DE - Defense World
Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Mackenzie Financial Corp Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
How the (TRDA) price action is used to our Advantage - news.stocktradersdaily.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC - Defense World
Entrada Therapeutics expands board with new director By Investing.com - Investing.com South Africa
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Entrada Therapeutics expands board with new director - Investing.com
Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News - GuruFocus
Entrada Therapeutics Appoints New Board Member - TipRanks
3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Buys 2,517 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Ex-Biogen Chief Medical Officer Strengthens Entrada's Duchenne Program as Phase 1 Data Shows Promise - Stock Titan
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Deutsche Bank AG Grows Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com - Investing.com South Africa
Entrada Therapeutics (TRDA) Gains EU Approval for Advanced Clinical Study | TRDA Stock News - GuruFocus
Entrada Therapeutics to start DMD trial in Q3 2025 - Investing.com
Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025 - Nasdaq
Breakthrough DMD Treatment Gets EU Green Light: Entrada's Novel Exon 45 Therapy Heads to Clinical Trials - Stock Titan
HC Wainwright Brokers Boost Earnings Estimates for TRDA - Defense World
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Q2 Earnings Forecast for TRDA Issued By HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
0.86%
0.10%
자본화:
|
볼륨(24시간):